These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 20354022)

  • 1. Europe's opportunity to open up drug regulation.
    Garattini S; Bertele' V
    BMJ; 2010 Mar; 340():c1578. PubMed ID: 20354022
    [No Abstract]   [Full Text] [Related]  

  • 2. Implications of international drug approval systems on confidentiality of business secrets in the U.S. pharmaceutical industry.
    O'Reilly JT
    Food Drug Law J; 1998; 53(1):123-32. PubMed ID: 11795328
    [No Abstract]   [Full Text] [Related]  

  • 3. Drug evaluation and approval process in the European Union.
    San Miguel MT; Vargas E
    Arthritis Rheum; 2006 Feb; 55(1):12-4. PubMed ID: 16463405
    [No Abstract]   [Full Text] [Related]  

  • 4. EU law mandates drug testing in children.
    Sinha G
    J Natl Cancer Inst; 2008 Jan; 100(2):84-5. PubMed ID: 18182609
    [No Abstract]   [Full Text] [Related]  

  • 5. [Experiences of the drug approval processes in the European Union].
    Pasanen M; Toivonen M
    Duodecim; 2000; 116(24):2817-22. PubMed ID: 12077887
    [No Abstract]   [Full Text] [Related]  

  • 6. Drug regulation in the European Union.
    Griffin JP
    Adverse Drug React Toxicol Rev; 2000 Aug; 19(3):179-206. PubMed ID: 11059359
    [No Abstract]   [Full Text] [Related]  

  • 7. The end of the beginning?
    Nat Biotechnol; 2006 Apr; 24(4):367. PubMed ID: 16601702
    [No Abstract]   [Full Text] [Related]  

  • 8. Adjusting Europe's drug regulation to public health needs.
    Garattini S; Bertele V
    Lancet; 2001 Jul; 358(9275):64-7. PubMed ID: 11454401
    [No Abstract]   [Full Text] [Related]  

  • 9. Biogenerics standoff.
    Herrera S
    Nat Biotechnol; 2004 Nov; 22(11):1343-6. PubMed ID: 15529145
    [No Abstract]   [Full Text] [Related]  

  • 10. Granting marketing authorisation for medicines in South East European countries: the point of view of the authority.
    Tomić S; Sucić AF; Martinac AI
    Regul Toxicol Pharmacol; 2010; 57(2-3):325-32. PubMed ID: 20385190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Marketing of pediatric drugs].
    Pabst JY
    Soins Pediatr Pueric; 2003; (210):18-9. PubMed ID: 12683130
    [No Abstract]   [Full Text] [Related]  

  • 12. [The change of the new veterinary drug legislation for delivery of veterinary drugs].
    Schutte F
    Tijdschr Diergeneeskd; 2006 Jan; 131(2):54-5. PubMed ID: 16454094
    [No Abstract]   [Full Text] [Related]  

  • 13. Whistleblower vows to fight on.
    Dyer C
    BMJ; 2004 Jan; 328(7433):187. PubMed ID: 14739181
    [No Abstract]   [Full Text] [Related]  

  • 14. Availability of comparative trials for the assessment of new medicines in the European Union at the moment of market authorization.
    van Luijn JC; Gribnau FW; Leufkens HG
    Br J Clin Pharmacol; 2007 Feb; 63(2):159-62. PubMed ID: 17166187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulatory pathways in the European Union.
    Kohler M
    MAbs; 2011; 3(3):241-2. PubMed ID: 21487236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How similar do 'biosimilars' need to be?
    Schellekens H
    Nat Biotechnol; 2004 Nov; 22(11):1357-9. PubMed ID: 15529154
    [No Abstract]   [Full Text] [Related]  

  • 17. EMEA struggles with need to restructure.
    Sheridan C
    Nat Biotechnol; 2003 Oct; 21(10):1118-9. PubMed ID: 14520381
    [No Abstract]   [Full Text] [Related]  

  • 18. Recent developments help the defense of drug companies in 10b-5 cases.
    Salpeter AN; Hutchins H
    Food Drug Law J; 1996; 51(3):345-53. PubMed ID: 11797711
    [No Abstract]   [Full Text] [Related]  

  • 19. Safe drugs and the cost of good intentions.
    Eichler HG; Abadie E; Raine JM; Salmonson T
    N Engl J Med; 2009 Apr; 360(14):1378-80. PubMed ID: 19339718
    [No Abstract]   [Full Text] [Related]  

  • 20. Informed by the European Union experience: what the United States can anticipate and learn from the European Union's regulatory approach to biosimilars.
    Gitter DM
    Seton Hall Law Rev; 2011; 41(2):559-92. PubMed ID: 21739759
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.